Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin versus empagliflozin in acute myocardial infarction
IRCT20240609062050N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myocardial infarction (MI) comparing Dapagliflozin with Empagliflozin (2 arms). Primary endpoints: Triglyceride-glucose index, Fasting blood glucose and 5 more. Started May 2026; status: completed.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20240609062050N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240609062050N2.